Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 159-166

  Lee, Sung Ji ^a   Cho, Sang Hee ^a   Yoon, Ju Young ^a   Hwang, Jun Eul ^a   Bae, Woo Kyun ^a   Shim, Hyun Jeong ^a   Chung, Ik Joo ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

Gastric cancer; S 1; Salvage therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; PACLITAXEL; PAIN; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 70349617451     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1019-4     Document Type: Article

References (44)

1. JR Kelley JM Duggan 2003 Gastric cancer epidemiology and risk factors J Clin Epidemiol 56 1 9 12589864 10.1016/S0895-4356(02)00534-6 (Pubitemid 36183309)
2. HR Shin KW Jung YJ Won JG Park 2004 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals Cancer Res Treat 36 103 114
3. SR Alberts A Cervantes CJ van de Velde 2003 Gastric cancer: epidemiology, pathology and treatment Ann Oncol 14 31 36
4. M Findlay D Cunningham A Norman J Mansi M Nicolson T Hickish V Nicolson A Nash N Sacks H Ford 1994 A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) Ann Oncol 5 609 616 7993836
5. AJ Lacave FJ Barón LM Antón E Estrada LM De Sande I Palacio E Esteban JM Gracia JM Buesa OA Fernández 1991 Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial Ann Oncol 2 751 754 1801881
6. P Rougier M Ducreux M Mahjoubi JP Pignon S Bellefqih J Oliveira C Bognel P Lasser M Ychou D Elias 1994 Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis Eur J Cancer 30A 1263 1269 7999410 10.1016/0959-8049(94)90170-8 (Pubitemid 24322059)
7. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991 4997 17075117 10.1200/JCO.2006.06.8429 (Pubitemid 46631401)
8. J Hwang SH Cho HJ Shim SR Lee JS Ahn DH Yang YK Kim JJ Lee HJ Kim IJ Chung 2008 Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer J Korean Med Sci 23 586 591 18756042 10.3346/jkms.2008.23.4.586
9. GV Kornek M Raderer B Schüll W Fiebiger C Gedlicka A Lenauer D Depisch B Schneeweiss F Lang W Scheithauer 2002 Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer Br J Cancer 86 1858 1863 12085176 10.1038/sj.bjc.6600345 (Pubitemid 34893241)
10. Y Hsu AK Sood JI Sorosky 2004 Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer Am J Clin Oncol 27 14 18 14758127 10.1097/01.coc.0000045849.95834.6B (Pubitemid 38176285)
11. SH Park WK Lee M Chung Y Lee SH Han SM Bang EK Cho DB Shin JH Lee 2006 Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil Anticancer Drugs 17 225 229 16428942 10.1097/00001813-200602000-00015
12. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 9893658 10.1016/S0959-8049(98)00211-1 (Pubitemid 28474225)
13. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 10765119 10.1159/000012099
14. HC Jeung SY Rha SJ Shin JB Ahn SH Noh JK Roh HC Chung 2007 A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status Br J Cancer 20 458 463 10.1038/sj.bjc.6603902 (Pubitemid 47258455)
15. I Takahashi Y Kakeji Y Emi M Sakurai Y Yonemura Y Kimura Y Maehara 2003 S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects Gastric Cancer 6 28 33 12775017 10.1007/s10120-003-0228-5 (Pubitemid 36604653)
16. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205
17. D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman R Heelan C Lightdale V Vinciguerra M Brennan 1992 FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 425 433
18. A Lerner R Gonin GD Steele Jr RJ Mayer 1992 Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial J Clin Oncol 10 536 540 1548518
19. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 10.3322/canjclin.55.2.74
20. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 8508427 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P
21. S Pyrhönen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 7533517
22. B Glimelius K Ekström K Hoffman W Graf PO Sjödén U Haglund C Svensson LK Enander T Linné H Sellström R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 9093725 10.1023/A:1008243606668 (Pubitemid 27112884)
23. S Cascinu F Graziano N Cardarelli M Marcellini P Giordani ET Menichetti G Catalano 1998 Phase II study of paclitaxel in pretreated advanced gastric cancer Anticancer Drugs 9 307 310 9635920 10.1097/00001813-199804000-00003
24. GP Stathopoulos SK Rigatos G Fountzilas A Polyzos JG Stathopoulos 2002 Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study Oncol Rep 9 89 92 11748462
25. F Graziano V Catalano AM Baldelli P Giordani E Testa V Lai G Catalano N Battelli S Cascinu 2000 A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer Ann Oncol 11 1263 1266 11106114 10.1023/A:1008373814453 (Pubitemid 30832248)
26. KE Schmid GV Kornek B Schüll M Raderer A Lenauer D Depisch F Lang W Scheithauer 2003 Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed Onkologie 26 255 258 12845210 10.1159/000071621 (Pubitemid 36831214)
27. F Giuliani V Gebbia F De Vita E Maiello M Di Bisceglie G Catalano N Gebbia G Colucci 2003 Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.) Anticancer Res 23 4219 4222 14666628
28. JL Lee MH Ryu HM Chang TW Kim JH Yook ST Oh BS Kim M Kim YJ Chun JS Lee YK Kang 2008 A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy Cancer Chemother Pharmacol 61 631 637 17520252 10.1007/s00280-007- 0516-6
29. SJ Sym MH Ryu JL Lee HM Chang TW Kim SS Lee JS Lee YK Kang 2008 Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane Am J Clin Oncol 31 151 156 18391599 10.1097/COC. 0b013e31815878a2
30. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 8862723 10.1097/00001813-199607000-00010
31. HC Jeung SY Rha HK Kim HY Lim S Kim SY Kim SJ Gong CH Park JB Ahn SH Noh HC Chung 2007 Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations Oncologist 12 543 554 17522242 10.1634/theoncologist.12-5-543 (Pubitemid 350012117)
32. P Schöffski 2004 The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors Anticancer Drugs 15 85 106 15075664 10.1097/00001813-200402000-00001
33. K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi T Taguchi 1999 An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202 210 10545788 10.1159/000012032 (Pubitemid 29481693)
34. F Nagashima A Ohtsu S Yoshida K Ito 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6 11 15747168 10.1007/s10120-004-0306-3 (Pubitemid 40394918)
35. O Kobayashi K Konishi M Kanari H Cho T Yoshikawa A Tsuburaya M Sairenji H Motohashi 2002 Unusual survival for more than 2 years with peritoneal metastases of gastric cancer Gastric Cancer 5 47 50 12021860 10.1007/s101200200007 (Pubitemid 34496352)
36. K Fujitani T Tsujinaka M Hirao 2003 Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding Hepatogastroenterology 50 889 892 12828112
37. H Osugi N Takada M Takemura S Kaseno S Lee M Ueno Y Tanaka K Fukuhara Y Fujiwara H Kinoshita 2002 Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination Oncol Rep 9 811 815 12066214
38. T Mori Y Fujiwara M Yano S Tamura T Yasuda S Takiguchi M Monden 2003 Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer Gastric Cancer 6 13 18 12775014 10.1007/s10120-003-0226-7 (Pubitemid 36604650)
39. DY Kim JH Kim SH Lee TY Kim DS Heo YJ Bang NK Kim 2003 Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 383 387 12598342 10.1093/annonc/mdg106 (Pubitemid 36367414)
40. SG Kim SY Oh HC Kwon S Lee JH Kim SH Kim HJ Kim 2007 A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer Jpn J Clin Oncol 37 744 749 17923456 10.1093/jjco/hym103 (Pubitemid 350123351)
41. S Ueda S Hironaka N Boku A Fukutomi T Yoshino Y Onozawa 2006 Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer Gastric Cancer 9 203 207 16952039 10.1007/s10120-006-0379-2 (Pubitemid 44426894)
42. SH Park EY Choi SM Bang EK Cho JH Lee DB Shin W Ki Lee M Chung 2005 Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes Anticancer Drugs 16 621 625 15930889 10.1097/00001813-200507000-00005 (Pubitemid 40867293)
43. ST Kim WK Kang JH Kang KW Park J Lee SH Lee JO Park K Kim WS Kim CW Jung YS Park YH Im K Park 2005 Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane and cisplatin refractory, metastatic gastric cancer Br J Cancer 92 1850 1854 15870718 10.1038/sj.bjc.6602575 (Pubitemid 40826132)
44. O Sencan A Buyukcelik B Yalcin MC Boruban H Akbulut A Demirkazik FC Senler H Onur F Icli 2008 The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma Eur J Cancer Care 17 26 32